PHILADELPHIA — (Oct. 17, 2019) — The Wistar Institute and collaborating institutions have received a major grant from the National Institutes of Health to further research on new melanoma targeted therapies integrating the role of the tumor microe…
PHILADELPHIA — (Oct. 9, 2019) — Scientists at The Wistar Institute described a novel mechanism through which astrocytes, the most abundant supporting cells in the brain, also promote cancer cell growth and metastasis in the brain. According to a s…
Wistar trainees voted Dr. Emilio Sanseviero, postdoctoral fellow in the Gabrilovich lab, and Keerthana Gnanapradeepan, graduate student in the Murphy lab, winners of the 2019 Annual Rugart Family Awards for best Research-in-Progress (RIP) presenta…
A community of supporters—including Wistar scientific leadership and Leadership Council members—came out to meet and welcome Wistar’s first Caspar Wistar Fellow: Dr. Rahul Shinde. Dr. Dario Altieri, Wistar president & CEO, spoke to how the Fel…
PHILADELPHIA — (Oct. 3, 2019) — A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types. This cell-permeable peptidomimetic was designed to disrupt a newl…
PHILADELPHIA — (October 1, 2019) — The National Institutes of Health (NIH) today announced that Zachary T. Schug, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at The Wistar Institute, was awarded the prestigious N…
PHILADELPHIA – September 25, 2019 – The Wistar Institute, a global leader in cancer, immunology and infectious disease research, has selected Integral Molecular, Inc. as the first industry partner for its Biomedical Research Technician (BRT) Appre…
PHILADELPHIA — (September 24, 2019) — The Wistar Institute was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisci…
PHILADELPHIA — (Sept. 18, 2019) — Researchers at The Wistar Institute have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein could represent a promising therapeutic target. The…
Wistar is pleased to announce Dr. Zachary Schug has been awarded a $450,000 grant from Susan G. Komen Philadelphia for breast cancer research. Schug studies breast cancer cells when they metastasize to the brain, and how to block or starve brain m…
